Drugs / BCMA/GPRC5D CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07196124 | Oct 2025 → Oct 2028 | plasma cell myeloma | Guangzhou Bio-gene Technology Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA/GPRC5D CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07196124 ↗ |
| Modality | Cell therapy | “BCMA/GPRC5D CAR-T cell infusion” NCT07196124 ↗ |
| Route | Intravenous | “administered intravenously” NCT07196124 ↗ |